| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278537A2 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
| 01/29/2003 | EP1278535A2 Uses of tgap7 for the modulation of leucocyte activation |
| 01/29/2003 | EP1278534A1 Methods and compositions for impairing multiplication of hiv-1 |
| 01/29/2003 | EP1278529A2 Therapeutic uses for mesenchymal stromal cells |
| 01/29/2003 | EP1002110B1 Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
| 01/29/2003 | EP0858465B1 Anti-tumoral protein |
| 01/29/2003 | EP0690732B1 Gas driven gene delivery instrument |
| 01/28/2003 | US6512102 Compositions and methods of diagnosis and treatment using casein kinase I |
| 01/28/2003 | US6512091 BRCA1 mutations, PCR primers and hybridization probes used in nucleic acid-based methods for diagnosis; presence or absence of the translation product of BRCA1 alleles |
| 01/28/2003 | US6511847 Recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect in the transfected cells; tumor suppressor gene |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511823 Novel DNA and amino acid sequences; expression vectors and host cells useful in a method for production of the HBNF protein |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511801 HIV-1 group O strain gp160 env precursor protein comprising the amino acid sequence of SEQ ID NO:100 |
| 01/28/2003 | US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006691A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | WO2003006662A1 Anti-neoplastic viral agents |
| 01/23/2003 | WO2003006658A1 Mutant herpes simplex virus that expresses yeast cytosine deaminase |
| 01/23/2003 | WO2003006657A2 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours |
| 01/23/2003 | WO2003006654A2 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006640A1 A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 01/23/2003 | WO2003006639A1 Cell and transgenic animal modelling human antigenic presentation and their uses |
| 01/23/2003 | WO2003006636A1 Reduction of the stimulatory capacity of antigen-presenting cells |
| 01/23/2003 | WO2003006616A2 Pseudotyped adeno-associated viruses and uses thereof |
| 01/23/2003 | WO2003006612A2 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006608A2 Enhancement of transfection of dna into the liver |
| 01/23/2003 | WO2003006607A2 Inhibition of apoptosis process and improvement of cell performance |
| 01/23/2003 | WO2003006479A1 Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006068A1 Gene therapy for dry eye syndrome |
| 01/23/2003 | WO2003006067A2 Composition comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006043A1 Surfactant peptide nanostructures, and uses thereof |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2003005961A2 A controlled release biodegradable gel matrix |
| 01/23/2003 | WO2003005812A2 Modulation of metabolism of steroids and xenobiotics |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002047731A3 Drug delivery compositions and coated medical devices |
| 01/23/2003 | WO2002046364A9 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/23/2003 | WO2002036790A3 Influenza virus vector for infection of dendritic cells |
| 01/23/2003 | WO2002036767A3 Therapeutic oligonucleotides of reduced toxicity |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002031162A3 Regulation of human phospholipase a2-like enzyme |
| 01/23/2003 | WO2002024906A9 Induction of exon skipping in eukaryotic cells |
| 01/23/2003 | WO2002020773A3 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002016598A3 Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers |
| 01/23/2003 | WO2002016553A3 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 01/23/2003 | WO2002010418A3 Targeting through integrins |
| 01/23/2003 | WO2002006330A3 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor |
| 01/23/2003 | WO2002000258A8 Medicinal compositions for angiogenic therapy |
| 01/23/2003 | WO2001097843A3 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 01/23/2003 | WO2001090365A3 Human protein kinase '13305' and uses therefor |
| 01/23/2003 | WO2001089583A3 Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases |
| 01/23/2003 | WO2001089548A3 Pharmaceutical use of fibulin-1 |
| 01/23/2003 | WO2001089364A3 Hcv variants |
| 01/23/2003 | WO2001077334A9 Lactococcus lactis genome, polypeptides and uses |
| 01/23/2003 | WO2001063279A3 Method of identifying toxic agents using differential gene expression |
| 01/23/2003 | US20030018986 Polynucleotide |
| 01/23/2003 | US20030018984 IGF-I expression system and methods of use |
| 01/23/2003 | US20030018184 Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018178 Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| 01/23/2003 | US20030018165 Uses of suppressive macrophage activation factors |
| 01/23/2003 | US20030018007 Compositions and methods for inducing gene expression |
| 01/23/2003 | US20030018006 Gene expression; plasmids; cancer therapy |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030018004 Vector |
| 01/23/2003 | US20030018002 Gene therapy |
| 01/23/2003 | US20030018001 Antitumor agents; anticarcinogenic agents |
| 01/23/2003 | US20030017979 Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases |
| 01/23/2003 | US20030017972 Drug delivery |
| 01/23/2003 | US20030017969 Methods and pharmaceutical compositions for healing wounds |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017597 Expression vector for use in human diagnositics and therapeutics |
| 01/23/2003 | US20030017593 Vector for use as tool in gene therapy |
| 01/23/2003 | US20030017587 Embryonic stem cells, clinical applications and methods for expanding in vitro |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017564 Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017549 Nucleotide sequences coding polypeptide for use in the treatment of atherosclerosis, hypertension, stroke, asthma, gastrointestinal, urogenital and sexual disorders |
| 01/23/2003 | US20030017547 Nucleotide sequences coding polypeptide for use in the treatment of cancer |
| 01/23/2003 | US20030017536 Novel polypeptide |
| 01/23/2003 | US20030017494 Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| 01/23/2003 | US20030017478 Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof |
| 01/23/2003 | US20030017466 Diagnosi and treatment of cancer; obtain tissue sample, monitor gene expression in sample, monitor methylation in sample, compare to control, evaluate for cancer |
| 01/23/2003 | US20030017456 Diagnosis and treatment and related preparations |
| 01/23/2003 | US20030017211 Method for drug delivery to the pulmonary system |